

**UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
CONSENT TO PARTICIPATE IN A RESEARCH STUDY**

Study Title: *Psilocybin therapy for depression and anxiety in Parkinson’s Disease: a pilot study*

Research Project Director:	Joshua Woolley, M.D., Ph.D., Associate Professor, Department of Psychiatry and Behavioral Science 401 Parnassus Ave, Medical Student Education LP 146 Box MSE0984 San Francisco, CA 94143
----------------------------	---

Study Coordinator:	Kimberly Sakai psilocybinstudies@ucsf.edu 415-221-4810 x24117
--------------------	---

This is a clinical research study. The study team leaders are **Josh Woolley M.D., Ph.D.**, and **Ellen Bradley M.D.**, from the UCSF Department of Psychiatry & Behavioral Sciences. A trained member of the study team will explain the study and discuss it with you. You can ask the team member questions at any time.

STUDY SUMMARY

Introduction: We are asking you to consider taking part in a research study being done by a team of doctors and scientists led by Drs. Josh Woolley M.D., Ph.D., and Ellen Bradley M.D., at UCSF.

The first part of this consent form summarizes the study. We will give you more details about the study later in this form. The study team will also explain the study to you and answer any questions you have.

Research studies include only people who choose to participate. It is your choice whether or not you want to participate in this study. Please take your time to make a decision about participating. You can discuss your decision with your family, friends, and health care team.

Purpose of the study: The purpose of this study is to understand whether people with Parkinson’s Disease and depression and/or anxiety have improvement in their symptoms after psilocybin therapy. Psilocybin is a psychedelic drug and the active ingredient in “magic mushrooms.” Recent studies have shown that psilocybin may improve depression and anxiety in people with cancer. We believe that it may also be helpful for people living with Parkinson’s Disease who have depression and anxiety, but this has not been tested yet.

Study Procedures: If you choose to participate in this study, you will complete a total of approximately 14 sessions (some in-person and others via video call), each of which will last 1-6 hours depending on the session. You will also come to the research unit at UCSF for two longer sessions. During these longer sessions, you will take a dose of psilocybin in the morning and stay

throughout the day and overnight. You will be paired with a team of trained facilitators for the duration of the study. During study sessions, you will participate in symptom assessments, fill out questionnaires, and meet with your facilitators. Depending on your specific schedule, you will be involved in the study for about 20 weeks.

You will designate a caregiver/support person that you have frequent contact with. They must be available to accompany you home the morning after each psilocybin dosing session (Visits A0 & B0). This is to ensure your safety. Your caregiver/support person will also complete a series of questionnaires and brief interviews to give their perspective on your health and well-being.

Possible Risks: There are risks to taking part in a research study. The most likely risks of psilocybin in the hours after you take it include:

- Nausea
- Blurred vision and dilated pupils
- Headache
- Mild to moderate increase in heart rate and blood pressure
- Anxiety and fear

There are also rare but serious risks of psilocybin that may last after the drug wears off. These may include:

- Psychosis (for example, seeing things that are not really there or feeling paranoid)

We will tell you about other risks of participating in the study later in this consent form.

Possible Benefits: You may benefit from participating in the study, but this cannot be guaranteed.

Your Other Options: You do not have to participate in this study. Your other choices may include:

- Getting treatment or care for your condition without being in a study.
- Taking part in another study.
- Getting no treatment

Please talk to your health care team about your choices before agreeing to participate in this study.

Following is a more complete description of this study. Please read this description carefully. You can ask any questions you want to help you decide whether to join the study. If you join this study, we will give you a signed copy of this form to keep for future reference.

DETAILED STUDY INFORMATION

This part of the consent form gives you more detailed information about what the study involves.

Research studies include only people who choose to take part. Please take your time to make your decision about participating. You can discuss your decision with your family and friends and with your health care team. If you have any questions, please ask a study team member.

You are being invited to take part in this study because you have been diagnosed with Parkinson's Disease and have depression and/or anxiety that causes distress in your life.

Why is this study being done?

The purpose of this study is to understand whether psilocybin therapy is likely to be a safe and feasible way to improve depression and/or anxiety for people with Parkinson's Disease. Depression and anxiety are common problems for people with Parkinson's Disease, but treatments are not effective for everyone. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms." Psilocybin is currently being studied in clinical trials and has no current medical use in the United States. Other studies have shown that a dose of psilocybin may improve depression and anxiety in people with cancer. We believe that it may also be helpful for people living with Parkinson's Disease who have depression and anxiety, but this has not been tested yet. Previous psilocybin studies have not included any participants with Parkinson's Disease.

Who pays for this study?

The study leaders, Josh Woolley, MD, PhD, and Ellen Bradley, MD, are doctors and faculty members employed by UCSF. Dr. Woolley, Dr. Bradley, and the study co-leaders will not receive any compensation beyond their usual salaries to conduct this study. Other study costs will be covered by charitable donations. The drug being tested in this study, psilocybin, will be provided by researchers at the non-profit Usona Institute. No patents pending are related to this study in any way.

Disclosure of financial or proprietary interests:

The investigators have the following disclosures related to this study:

Josh Woolley: Compensated consultant on the Scientific Advisory Board of Silo Pharma

Ellen Bradley: None

Patrick Finley: None

Jill Ostrem: None

How many people will take part in this study?

About 10 people with Parkinson's Disease will participate in this study, plus their caregivers/support people.

What will happen if I take part in this research study?

First, you will complete a series of assessments in-person and by video to confirm your eligibility for this study. This may take up to 6 hours. If you are eligible, you will meet your facilitators and complete two sessions to prepare for your psilocybin sessions. These will take about 2-3 hours each. At least one of these sessions will be in person at our research unit located in the UCSF Langley Porter Psychiatric Institute (LPPI; 401 Parnassus Ave, San Francisco, CA). Next, you will complete a longer session at our research unit during which you will take a dose

of psilocybin in the morning and stay all day and overnight. Your facilitators will be present all day, study staff will be present overnight, and one of our study physicians will be available the whole time. You will complete multiple follow-up sessions, both in-person and by video, over the next 2 weeks after that. Next, you will complete a second longer session at our research unit during which you will again take a dose of psilocybin in the morning and stay all day and overnight. Your facilitators will be present all day, study staff will be present overnight, and one of our study physicians will be available the whole time as for the first psilocybin session. The difference is that the dose of psilocybin may be higher during the second session. You will complete multiple follow-up sessions, both in person and by video, over the next 4 weeks after that. We will stay in contact with you until the last follow-up session, 12 weeks after your second psilocybin session.

Screening / Baseline Sessions:

You will need to complete the following exams, tests or procedures to confirm you are eligible for this study. These exams, tests or procedures are part of regular medical care and may be done even if you do not decide to join the study. If you have had some of them recently, you may not need to repeat them. This will be up to your study doctor. These can be broken into multiple visits if necessary.

- Questions about your general health and medical history, including your mental health
- Questions specifically about your Parkinson's symptoms
- Physical exam and vital signs
- "On/Off" assessment to measure your Parkinson's Disease motor symptoms both on and off medications (if you take medications for these symptoms)
- Electrocardiogram (ECG) where stickers will be placed on your body to detect the electric activity in your heart
- Blood draw where a needle will be inserted into a vein in your arm. A total of about five tablespoons of blood will be drawn for tests.
- Urine tests, including a urine drug screen for recent drug use and pregnancy test (if you can become pregnant).

Before the first psilocybin session:

If the exams, tests and procedures show that you can continue to be in the study and you choose to take part, then you will complete the following in-person / video sessions and procedures:

- Two preparation sessions with your facilitators. At least one of these will be in person. We will familiarize you with what to expect during your psilocybin session including the physical space where you will take psilocybin.
- We will talk with you about your physical and mental health, goals, and expectations for the psilocybin session.
- Each preparation session will take 2-3 hours.

First psilocybin session and follow up visits:

- Before taking psilocybin, study staff will put your belongings (e.g. phone, wallet, keys) in a secure location. This is to ensure your safety while you are on psilocybin. Items will be returned to you once the effects of psilocybin have worn off, after about 6 hours.
- You will be asked to complete urine tests, including a urine drug screen for recent drug use and pregnancy test (if you can become pregnant).
- During this psilocybin visit, you will be asked to take a 10mg capsule of oral psilocybin.
- While you are on psilocybin, your facilitators will monitor your heart, blood pressure, temperature, and how you are feeling. A study physician will be available at all times. You will stay overnight at the research unit in a private room.
- The next morning, you will talk with your facilitators about your psilocybin experience, your symptoms, and complete assessments before leaving the research unit.
- You will complete multiple follow-up sessions, both in-person and by video, over the next 2 weeks after that. At least one session will be in person. During the sessions, you will answer questions about your symptoms, psilocybin experience, and you will complete a series of assessments. We will also make a collaborative decision about whether you will take a higher psilocybin dose for the second session.

Second psilocybin dose and follow up visits:

- We will follow all the same procedures as for the first psilocybin session described above. This includes a urine drug screen for recent drug use and pregnancy test (if you can become pregnant). You will stay overnight at the research unit again as described above.
- During this psilocybin visit, you will be asked to take a 25mg capsule of oral psilocybin.
- The difference is that you may take a higher dose of psilocybin at this session if you and the study physician have agreed on that decision.
- You will complete multiple follow-up sessions, both in person and by video, over the next 4 weeks after that. During the visits, you will answer questions about your symptoms, psilocybin experience, and you will complete a series of assessments.
- We will stay in contact with you until the last follow-up session, 12 weeks after your second psilocybin session. This last follow-up session will be by phone.

Audio-video recording


We will be audio and video recording you during this study. We will use these recordings to understand your symptoms and also to make sure our study staff meet quality requirements. We will protect the confidentiality of all recordings by limiting access to them. Only study team members and researchers who are analyzing data from this study will be able to access the recordings. The recordings will be stored on encrypted computer drives that are kept in locked rooms at UCSF. They will be kept permanently and securely by the UCSF Department of Psychiatry and Behavioral Sciences.

We may share recordings with researchers at our university/other universities who are collaborating with us, or companies that are helping with data analysis (for example, we may

have a HIPAA-compliant, secure service transcribe audio recordings to text). Any data transferred outside of UCSF will involve a legally binding, signed agreement to make sure that collaborators use appropriate procedures to protect your privacy. We will not share your name or any additional personal information. When possible, we will only share de-identified data. Any data that we share with collaborators will be destroyed when we finish the analysis. Your data, including audiovisual recordings, will never be accessible to the general public.

Study Plan

The chart below shows an overview of the study with each of the study sessions on a timeline from top to bottom:



How long will I be in the study?

The total study length will be about 56 hours over 4-5 months, plus overnight time. This includes the time from your first in-person appointment to the last phone appointment about 3 months after your second psilocybin session.

Can I stop being in the study?

Yes. You can decide to stop at any time. If you are thinking about stopping or decide to stop, the study team leader will work with you to make sure that you are able to stop your participation safely.

Important Note: While you are under the effects of psilocybin (which last about 5-6 hours), you will not be able to stop being in the study. If you tell a study doctor, your facilitators, or another study staff member that you wish to stop being in the study, you will still have to stay at the research unit until the drug effects have worn off and it is safe for you to leave. This is because we must prioritize your safety while you are under the effects of psilocybin.

It is important to tell a study doctor if you are thinking about stopping so any risks from the psilocybin dose can be monitored. Another reason to tell a study doctor that you are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you.

One of the study doctors may stop you from taking part in this study at any time if they believe it is in your best interest, if you are not able follow the study rules, or if the study is stopped.

What side effects or risks can I expect from being in the study?

You may have side effects while on the study. The study staff will monitor you for any side effects. However, doctors don't know all the side effects that may happen. Side effects may be mild or very serious. Your health care team may give you medicines to help lessen side effects. Many side effects from psilocybin go away soon after the psilocybin session end. In some cases, side effects can be serious, long lasting, or may never go away.

You should talk to a study doctor about any side effects you experience while taking part in the study.

Medical risks and side effects related to taking psilocybin include those which are:

Likely

- Temporary elevations in heart rate and/or blood pressure during the psilocybin session
- Temporary anxiety or confusion during the psilocybin session
- Headache soon after the psilocybin session

Less Likely

- Nausea and/or vomiting during the psilocybin session
- Temporary slower movements or difficulty coordinating movements during the psilocybin session
- Temporary fatigue or difficulty sleeping the night after the psilocybin session

Rare but serious

- Elevated blood pressure during the psilocybin session that require medications to bring back to normal
- Elevated body temperature, muscle stiffness, and confusion during the psilocybin session due to serotonin syndrome (too much serotonin in the body)
- Anxiety, mania, or psychotic symptoms (like hallucinations or paranoia) soon after the psilocybin session that last for >24 hours after the drug wears off
- Anxiety, mania or psychotic symptoms during or after the psilocybin session that are severe and require medications to maintain your safety and/or the safety of study staff
- Unknown Risks: It is important to note that psilocybin may have side effects that no one knows about yet. For example, we do not know the effects of psilocybin on symptoms of Parkinson's Disease. The study leaders will let you know if they learn anything that might make you change your mind about participating in the study.

Other risks of participating in this study

- Blood Drawing (Venipuncture): Drawing blood may cause temporary discomfort from the needle stick, bruising, infection, and fainting.
- Reproductive risks: You should not become pregnant or have a baby while on this study because the drugs [or procedures] in this study can affect an unborn baby. In addition, you should not breastfeed a baby after taking psilocybin, because we do not know how psilocybin could affect the baby. If you can become pregnant, you and your partner must agree to use reliable birth control while you are participating in this study. Check with your study doctor about what kind of birth control methods to use and how long to use them. If you can become pregnant, we will have you complete a pregnancy test before you enter this study and before each psilocybin session. These tests must show that you are not pregnant in order for you to continue in the study. If you think you may be pregnant at any time during the study, tell your study staff right away
- Risk of loss of employment or violation of standard medical care practice: Please note that standard illicit drug testing do not typically test for psilocybin. If you are tested for psilocybin it may show on a urine / blood toxicology test for 1-3 days and hair toxicology tests for 90 days after ingestion.
- Loss of privacy

- For more information about risks and side effects, please ask the study leaders

Are there benefits to taking part in the study?

Taking part in this study may or may not make your health better. While doctors hope psilocybin therapy will help depression and anxiety for people with Parkinson's Disease, there is no proof of this yet. We do know that the information from this study will help doctors learn more about psilocybin therapy as a treatment for Parkinson's Disease. This information could help other patients.

What other choices do I have if I do not take part in this study?

Your other choices may include:

- Getting treatment or care for depression and/or anxiety without being in a study.
- Taking part in another study.
- Getting no treatment.

Please talk to your health care team about your choices before deciding if you will take part in this study.

How will my information be used?

Researchers will use your information to conduct this study. Once the study is done using your information, we may share it with other researchers so they can use it for other studies in the future. When possible, we will only share de-identified data sets. Your data, including audio and video recordings, will never be accessible to the general public. We will not ask you for additional permission to share this de-identified information.

In instances where de-identification of data is not possible (e.g. audio and video recordings), transfers outside of UCSF will involve a legally binding, signed agreement to make sure that collaborators use appropriate procedures to protect your privacy. We will not share your name or any additional personal information. Any data that we share with collaborators will be destroyed when we finish the analysis. Your personal information will never be accessible to the general public.

How will information about me be kept confidential?

Participation in research involves some loss of privacy. We will do our best to make sure that information about you is kept confidential, but we cannot guarantee total privacy. Some information from your medical records will be collected and used for this study. If you do not have a UCSF medical record, we will create one for you. Your signed consent form and some of your research tests will be added to your UCSF medical record. Therefore, people involved with your future care and insurance may become aware of your participation and of any information added to your medical record as a result of your participation. Study tests that are performed by research labs, and information gathered directly from you by the researchers will be part of your

research records but will not be added to your medical record. Your personal information may be given out if required by law.

Safety concerns may also lead to a loss of privacy. Specifically, if the study staff are concerned that you are at risk of harming yourself/suicidal, a study doctor will evaluate you as soon as possible. You may need to stop participating in the study and be hospitalized.

If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.

Authorized representatives from the following organizations may review your research data for the purpose of monitoring or managing the conduct of this study:

- University of California
- Food and Drug Administration (FDA)
- Research Advisory Panel of California

This study is covered by a Certificate of Confidentiality from the National Institutes of Health. This means that the researchers cannot release or use information, documents, or samples that may identify you in any legal action or suit unless you give approval. They also cannot provide your information, documents, or samples as evidence unless you have agreed. This protection includes federal, state, or local civil, criminal, administrative, legislative, or other proceedings. An example would be a court subpoena.

There are some important things about the Certificate of Confidentiality that you need to know. The Certificate DOES NOT stop reporting that federal, state or local laws require. Some examples are laws that require reporting of child or elder abuse, some communicable diseases, and threats to harm yourself or others. The Certificate CANNOT BE USED to stop a sponsoring United States federal or state government agency from checking records or evaluating programs. The Certificate DOES NOT stop disclosures required by the federal Food and Drug Administration (FDA). The Certificate also DOES NOT prevent your information from being used for other research if allowed by federal regulations.

Researchers may release information about you when you say it is okay. For example, you may give them permission to release information to insurers, medical providers or any other persons not connected with the research. The Certificate of Confidentiality does not stop YOU from willingly releasing information about your involvement in this research. It also does not prevent YOU from having access to your own information.

Are there any costs to me for taking part in this study?

No. The sponsor has agreed to pay for all items associated with this research study; you or your insurer will not be billed. The sponsor will provide psilocybin and pay for all of the assessments at no cost to you.

Will I be paid for taking part in this study?

In return for your time and effort, you will be paid up to \$500 for completing all parts of this study. We will provide compensation for the Screening/Baseline session (6 hours), Day A7 (3 hours), Day B7 (3 hours), Day B30 (3 hours), and Day B90 (1 hour) follow-up sessions at a rate of \$25/hr. If you complete all study sessions, you will be paid a \$100 bonus. This is a total of \$500. You may also receive up to a total of \$75 for the entire study for travel and parking for in-person appointments.

What happens if I am injured because I took part in this study?

It is important that you tell the study leaders, Drs. Joshua Woolley and/or Ellen Bradley, if you feel that you have been injured because of taking part in this study. You can tell them in person, call at 415 221-4810 x24117, or email PsilocybinStudies@ucsf.edu

Treatment and Compensation for Injury: If you are injured as a result of being in this study, the University of California will provide necessary medical treatment. The costs of the treatment may be billed to you or your insurer just like any other medical costs, or covered by the University of California, depending on a number of factors. The University of California do not normally provide any other form of compensation for injury. For further information about this, you can call the office of the Institutional Review Board at 415-476-1814.

What are my rights if I take part in this study?

You can choose either to take part or not to take part in the study. If you decide to take part in this study, you can leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your regular benefits. Leaving the study will not affect your medical care in any way. You can still get your medical care from our institution.

We will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment by signing this form.

Who can answer my questions about the study?

You can talk to the study leaders about any questions, concerns, or complaints you have about this study. You can reach Drs. Joshua Woolley or Ellen Bradley at 415-221-4810 x24117 or by emailing PsilocybinStudies@ucsf.edu

If you wish to ask questions about the study or your rights as a research participant to someone other than the study leaders or if you wish to voice any problems or concerns you may have about the study, please call the office of the Institutional Review Board at 415-476-1814.

A description of this clinical trial will be available on [ClinicalTrials.gov](https://clinicaltrials.gov), as required by U.S. Law. This Web site will not include any information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

CONSENT COMPREHENSION QUESTIONS

1. Participation in this study is voluntary and I may withdrawal at any time	T or F
2. I will be asked about my depression and/or anxiety symptoms	T or F
3. I will be asked to stay overnight at the research unit during psilocybin sessions	T or F
4. The purpose of this study is to understand whether people with Parkinson’s Disease with depression and/or anxiety have improvements in their symptoms after psilocybin therapy	T or F
5. I can drop out of the study at any time, but it is recommended that I first consult with the study doctor to make sure it is safe	T or F
6. Possible side effects of psilocybin include anxiety, nausea, and headache	T or F
7. How many times will you receive psilocybin?	_____

CONSENT

You have been given copies of this consent form and the Experimental Subject's Bill of Rights to keep.

You will be asked to sign a separate form authorizing access, use, creation, or disclosure of health information about you.

PARTICIPATION IN RESEARCH IS VOLUNTARY. You have the right to decline to participate or to withdraw at any point in this study without penalty or loss of benefits to which you are otherwise entitled.

You have read this information, which is printed in English. This is a language that you read and understand. If you wish to participate in this study, you should sign below.

Date

Participant's Signature for Consent

Date

Person Obtaining Consent

OPTIONAL CONSENT ITEMS
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Please read each sentence below and think about your choice. If you agree with any of the statements below, sign and put today's date.

If you have any questions, please ask the researchers, talk to your doctor, or call our research review board at (415) 476-1814. No matter what you decide to do, it will not affect your care or participation in this study.

1. Someone may contact me in the future to ask me to take part in more research.

Participant's Signature for Consent

Date